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Quality laboratory systems are 
essential for detecting and 
responding effectively to HIV 
and other diseases. CDC, 
through PEPFAR, has helped 
support the development of the 
following*: 
 
• More than 1,900 full and 
integrated, non-disease 
specific, clinical laboratories 
• More than 16,500 HIV testing 
sites throughout the world  
• Diagnostic assistance and 
training to in-country 
laboratories that collectively 
tested 11 million pregnant 
women for HIV, leading to the 
prevention of mother-to-child 
transmission and allowing 
230,000 infants to be born  
HIV-free (Fiscal year 2012) 
• Over 280 laboratories in 22 
countries working towards 
laboratory accreditation 
• National strategic plans for 
laboratories in 18 countries 
for the transition of laboratory 
systems and services to 
country ownership  
• 481 laboratorians trained 
from 23 countries through 




*Fiscal year 2011 unless 
otherwise indicated 
   
 
Global HIV/AIDS: International Laboratories  
CDC is establishing and strengthening international laboratories  
for rapid, effective disease response  
 
 strong national public health laboratory system is essential for responding effectively to HIV and other 
diseases, and is crucial to rapidly detect and control emerging global public health threats. As a key 
partner agency for the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), CDC works with countries to 
build high quality laboratory systems and services that are critical for HIV prevention, care and treatment, as 
well as for other diseases. CDC also works to leverage PEPFAR resources including laboratories by linking 
them to other mainstream healthcare services.  This integrated healthcare approach strengthens a country’s 
entire healthcare system. 
 
Scientific and technical expertise to establish high quality international 
laboratory systems and services  
 
CDC works with Ministries of Health to ensure that all scientific and technical aspects of laboratory 
procurement, standardization, quality control, and quality assurance are established by: 
 Building high quality laboratory systems and services for diagnosis in support of HIV care and 
treatment, prevention, and HIV/tuberculosis (TB) co-infection. CDC provides support on quality 
control and quality assurance of laboratories and testing activities. Examples include: 
- CDC, in collaboration with the World Health Organization (WHO), developed an HIV drug resistance 
detection tool to test dried blood spots that helped cut the cost of HIV drug resistance testing by 
almost 50%. 
- Working with Ministries of Health and other in-country partners, CDC implemented and expanded 
Early Infant Diagnosis (EID) services in more than 25 countries to give HIV-infected infants early access 
to appropriate care and treatment.  
- CDC developed training and quality assurance tools for HIV rapid testing that are widely implemented 
at thousands of testing sites in PEPFAR-supported countries. 
 Providing technical expertise for laboratory accreditation to expand and standardize the quality 
of laboratories for a sustainable system. Examples include: 
- CDC, in collaboration with WHO and African host governments, conceived and launched the first 
African laboratory accreditation program in 2009 to ensure that high quality laboratory networks 
are established and sustained. CDC also played a key role in developing a training program to 
support laboratory improvement and accelerate accreditation preparation. 
- CDC was instrumental in establishing the first African Society for Laboratory Medicine, a key 
organization for administering the laboratory accreditation program and strengthening capacity 
building for country ownership.  
- With support from CDC, national laboratories in Ethiopia and Kenya were accredited by WHO 
ResNet to perform quality-assured testing to support HIV drug-resistance surveillance. 
 Providing technical expertise on evaluation and implementation of equipment and assays for 
appropriate use and placement in PEPFAR-supported countries.    
- CDC evaluated the performance of a new point-of-care CD4 assay used to assess immune status of 
HIV-positive patients to determine antiretroviral drug eligibility.  
 
Critical leadership for transitioning sustainable laboratory systems and 
services to local country ownership 
 
CDC collaborates with Ministries of Health to build their capacity to establish and maintain  










 Providing technical expertise to develop national strategic plans for laboratories that help countries respond effectively to HIV and 
other diseases, and support the transition of laboratory systems and services to country ownership.  
 Providing on-site training and mentoring to develop a qualified local workforce capable of managing efficient laboratories that support 
quality assurance systems and timely, reliable testing. 
- CDC collaborated with the South Africa Ministry of Health to establish the African Centre for Integrated Laboratory Training in 
Johannesburg. 
- Through the African Society for Laboratory Medicine, CDC is working to develop in-country capacity to conduct laboratory-related 
research to facilitate evidence-based decision-making.   
- CDC, in collaboration with WHO, has developed a standardized laboratory training package for HIV drug resistance testing. 
 
Notable Accomplishments: International Laboratories 
Accreditation Program for Laboratory Quality Improvement 
CDC, in collaboration with the WHO Regional Office for Africa and 12 African governments, developed and implemented the first African laboratory 
accreditation program to provide better training and expand testing capacity. To support countries in achieving accreditation, CDC was instrumental in 
developing the Strengthening Laboratory Management towards Accreditation program. CDC also partnered with WHO to develop a corresponding 
checklist to monitor and improve the quality of laboratory results related to HIV/AIDS and other diseases, including for rapid identification of emerging 
health threats. 
African Society of Laboratory Medicine 
CDC was instrumental in establishing the first-of-its-kind African Society of Laboratory Medicine (ASLM) in collaboration with WHO, Ministries of Health, 
the African Union, and other partners. ASLM serves as a professional body to guide and strengthen laboratory network development in Africa. It is 
composed of African Ministries of Health and sub-Sahara African laboratorians as well as other local, national, and international leaders, and partners, 
who will serve as the accrediting body for the laboratory accreditation program.   
Regional Center of Excellence for Laboratory Training 
CDC helped establish the African Centre for Integrated Laboratory Training in Johannesburg, South Africa, which serves as a regional training center to 
increase the pool of laboratory technicians and health care workers trained in HIV and tuberculosis diagnostics throughout Africa.  Hundreds of 
laboratory scientists and managers from over 20 countries in sub-Saharan Africa, Asia, and the Caribbean have participated in this intensive hands-on 
training. Currently, CDC is working to establish regional training centers for West and East Africa. 
National Strategic Plans for Laboratories 
To further promote country ownership while building capacity, CDC has partnered with Ministries of Health to support the development of national 
strategic plans for laboratories. Using CDC’s integrated, non disease-specific approach to strengthen laboratory systems, these plans support all health 
sectors, build efficiencies, and enable countries to respond effectively to HIV and other diseases, including emerging public health threats. For the first 
time, 18 African Ministries of Health now have fully integrated and comprehensive laboratory plans.  
Ensuring the Quality of HIV Testing 
CDC has established a standardized program to validate new HIV rapid tests for potential use in PEPFAR-supported countries. The program is unique in 
that it uses a large panel of well characterized specimens from all over the world to assess test performance. In the last 5 years, more than 40 new kits 
have been evaluated; one-third were rejected because they failed to meet the performance standards.  CDC also developed simple and practical quality 
assurance tools that are widely used in countries to monitor and ensure quality of HIV rapid testing.       
Early Infant Diagnosis for Early Access to Care and Treatment 
Studies show that, left unidentified and untreated, 50-60% of HIV-infected infants die by age two. CDC led the development of the Early Infant 
Diagnosis (EID) testing procedure that gives HIV-infected infants early access to diagnosis and appropriate care and treatment. With a simple prick of an 
infant’s heel, toe, or finger, blood is placed onto a card to dry, creating samples that remain stable for relatively long periods without refrigeration, 
making them simple to transport for testing. CDC has worked with Ministries of Health and other in-country partners to implement and expand EID 
services in more than 25 countries. To ensure quality testing, CDC also developed and administered an EID testing program to more than 100 
laboratories in 40 countries.  
HIV Drug Resistance Testing and Training 
In Asia, Central America, and Africa, CDC provided technical support and training to 18 countries for HIV drug-resistance testing. CDC developed a low 
cost, broadly sensitive genotyping assay that cut the reagent cost for HIV drug-resistance testing by 70% and was implemented in the National Drug 
Resistance Laboratories in Ethiopia, Kenya, South Africa, and Tanzania. The assay, which uses dried blood spot technology, made HIV drug-resistance 
testing in remote areas a reality.  
Viral load testing for monitoring patients on highly active antiretroviral therapy (HAART) 
As more persons are identified as HIV-positive and receive antiretroviral treatment, there are pressing needs to monitor the viral load.  Typically, viral-
load testing requires human plasma but CDC is leading the push towards using dried blood spots (DBS) in resource-limited settings.  CDC developed 
training curricula for viral-load testing on two major molecular platforms and is offering training on DBS collection and testing. To ensure quality viral 
load testing, CDC also developed and administered a novel dried tube specimen viral-load proficiency testing program  
to more than 100 laboratories in 40 countries. 
